86520-63-0 Usage
Description
.alpha.-D-Galactopyranose, 2,3,4,6-tetraacetate 1-(2,2,2-trichloroethanimidate), also known as 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl Trichloroacetimidate (CAS# 86520-63-0), is a complex organic compound derived from galactose, a monosaccharide sugar. It is characterized by the presence of four acetyl groups at the 2, 3, 4, and 6 positions and a trichloroethanimidate group at the 1 position. .alpha.-D-Galactopyranose, 2,3,4,6-tetraacetate 1-(2,2,2-trichloroethanimidate) is known for its potential applications in various fields, particularly in organic synthesis.
Uses
Used in Organic Synthesis:
.alpha.-D-Galactopyranose, 2,3,4,6-tetraacetate 1-(2,2,2-trichloroethanimidate) is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structure allows for selective reactions and modifications, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Carbohydrate Chemistry:
In the field of carbohydrate chemistry, .alpha.-D-Galactopyranose, 2,3,4,6-tetraacetate 1-(2,2,2-trichloroethanimidate) serves as a versatile reagent for the synthesis of oligosaccharides, glycoconjugates, and other carbohydrate-based compounds. Its acetylated and trichloroethanimidate functionalities facilitate efficient glycosylation reactions, enabling the formation of complex carbohydrate structures with high selectivity and yield.
Used in Drug Development:
.alpha.-D-Galactopyranose, 2,3,4,6-tetraacetate 1-(2,2,2-trichloroethanimidate) is also utilized in drug development as a potential pharmaceutical agent or as a precursor for the synthesis of bioactive molecules. Its unique structure and reactivity make it a promising candidate for the development of new drugs targeting various diseases and conditions.
Used in Material Science:
In material science, .alpha.-D-Galactopyranose, 2,3,4,6-tetraacetate 1-(2,2,2-trichloroethanimidate) can be employed in the design and synthesis of novel materials with specific properties, such as stimuli-responsive hydrogels, self-assembling systems, and functional coatings. Its ability to form stable glycosidic linkages and its compatibility with various polymers and materials make it a valuable component in the development of advanced materials for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 86520-63-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,5,2 and 0 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 86520-63:
(7*8)+(6*6)+(5*5)+(4*2)+(3*0)+(2*6)+(1*3)=140
140 % 10 = 0
So 86520-63-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H20Cl3NO10/c1-6(21)25-5-10-11(26-7(2)22)12(27-8(3)23)13(28-9(4)24)14(29-10)30-15(20)16(17,18)19/h10-14,20H,5H2,1-4H3/t10-,11-,12-,13-,14+/m0/s1
86520-63-0Relevant articles and documents
PROCESS OF SYNTHESIS OF β-6'SULFOQUINOVOSYL DIACYLGLYCEROLS
-
Page/Page column 11; 12, (2022/02/28)
The present invention relates to a synthesis process of β-6-sulfoquinovosyl-diacylglycerols. In particular, said process is for the synthesis of the compounds 1,2-O-distearoyl-3-O-(β- sulfoquinovosyl)-R/S-glycerol, 1,2-O-distearoyl-3-O-(β-sulfoquinovosyl)-R-glycerol or 1,2- O-distearoyl-3-O-(β-sulfoquinovosyl)-S-glycerol, named respectively Sulfavant A, Sulfavant R and Sulfavant S.
Synthesis of malformin-A1, C, a glycan, and an aglycon analog: Potential scaffolds for targeted cancer therapy
Andreana, Peter R.,Hossain, Farzana,Nishat, Sharmeen
, (2022/02/21)
Improvement in therapeutic efficacy while reducing chemotherapeutic side effects remains a vital objective in synthetic design for cancer treatment. In keeping with the ethos of therapeutic development and inspired by the Warburg effect for augmenting biological activities of the malformin family of cyclic-peptide natural products, specifically anti-tumor activity, a β-glucoside of malformin C has been designed and synthesized utilizing precise glycosylation and solution phase peptide synthesis. We optimized several glycosylation procedures utilizing different donors and acceptors. The overarching goal of this study was to ensure a targeted delivery of a glyco-malformin C analog through the coupling of D-glucose moiety; selective transport via glucose transporters (GLUTs) into tumor cells, followed by hydrolysis in the tumor microenvironment releasing the active malformin C a glycon analog. Furthermore, total synthesis of malformin C was carried out with overall improved strategies avoiding unwanted side reactions thus increasing easier purification. We also report on an improved solid phase peptide synthesis protocol for malformin A1.
Nitrogen-containing aromatic ring derivative containing galactose and application thereof
-
Paragraph 0159; 0161-0163, (2021/06/09)
The invention belongs to the technical field of medicines, and relates to a nitrogen-containing aromatic ring derivative containing galactose, application thereof and a pharmaceutical composition containing the compound. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in prevention or treatment of tumors, inflammatory diseases, autoimmune diseases and other diseases, especially tumors.
